Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

Sana Biotechnology, Inc.
Next earnings Aug 10, 2026 (after close) · consensus $-0.15 EPS
Last earnings +1.4% on 2026-05-11
Mixed signals in the latest filings.
Sana Biotechnology, Inc. shows limited reported revenue, and -151.8% ROE.
Sources: SEC EDGAR (CIK 0001770121, latest 10-Q filed 2026-05-11) · EODHD · as of 6/22/2026, 11:11:36 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$357M | -$273M | -$293M | -$273M | -$250M |
| Net income | -$356M | -$269M | -$283M | -$267M | -$244M |
| Diluted EPS | -$2.14 | -$1.43 | -$1.46 | -$1.16 | -$0.96 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.